- Home
- NRXS vs RFL Comparison
NRXS vs RFL Comparison
Compare NRXS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NRXS | RFL |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 92.6M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NRXS | RFL |
|---|---|---|
| Price | $7.07 | $2.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 114.1K | ★ 247.5K |
| Earning Date | 05-12-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.13 | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,569,282.00 | $917,000.00 |
| Revenue This Year | $172.91 | N/A |
| Revenue Next Year | $115.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 32.89 | ★ 43.96 |
| 52 Week Low | $2.20 | $1.12 |
| 52 Week High | $9.33 | $2.84 |
Technical Indicators
Market Signals| Indicator | NRXS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 77.22 |
| Support Level | $6.79 | $1.22 |
| Resistance Level | $7.79 | N/A |
| Average True Range (ATR) | 0.36 | 0.28 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 73.44 | 90.26 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.